Streetbeat News

Products Services

APVO

Aptevo Therapeutics shares rose following positive interim data from a Phase 1 trial of ALG.APV-527 monotherapy, with 60% of patients achieving stable disease in a solid tumor study.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:13 pm

APVO

Aptevo Therapeutics and Alligator Bioscience have announced interim data from a Phase 1 trial of their monotherapy ALG.APV-527. The trial showed that 60% of evaluable patients achieved stable disease in a study focused on solid tumors.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:12 pm

KRRO

NVO

Korro Bio has announced a collaboration with Novo Nordisk to develop two therapeutic candidates using Korro's OPERA platform for RNA editing, targeting cardiometabolic diseases. The deal is valued at up to $530 million, including milestone payments, royalties, and R&D funding.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:12 pm

DOGEUSD

FLOKIUSD

SHIBUSD

Glauber Contessoto, known as the 'Dogecoin millionaire,' predicts a 2025 meme coin bull run, highlighting Pepe and Brett as key players. He foresees a resurgence in the 'Dogeverse' with Dogecoin, Shiba Inu, and Floki gaining traction.

Portfolio Pulse from Khyathi Dalal

September 16, 2024 | 12:10 pm

APLM

Apollomics Inc. presented data on Vebreltinib for treating non-small cell lung cancer with METex14 skipping mutations at the 2024 ESMO Congress.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:10 pm

TKLF

Yoshitsu Co. (NASDAQ:TKLF) is expanding its Reiwatakiya brand with two new franchise stores in Hong Kong, aiming to enhance market presence and brand recognition in Asia.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:09 pm

NXTC

NextCure presented results from a Phase 1b study of NC410 in combination with Pembrolizumab at ESMO 2024, showing biomarker data that support the proposed mechanism of action of NC410.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:09 pm

ITOS

NCNA

ZNTL

NuCana's stock surged 282% after presenting positive Phase 2 study data at the ESMO Congress. Zentalis Pharmaceuticals' shares rose 49% following the FDA lifting a partial clinical hold on azenosertib studies. iTeos Therapeutics' shares fell 16% after releasing interim data from GALAXIES Lung-201.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:08 pm

VERA

Vera Therapeutics, Inc. (NASDAQ:VERA) will host an R&D Day on October 2, 2024, to discuss potential indication expansion for their drug atacicept. The event will feature notable medical experts and focus on expanded R&D activities beyond current clinical programs.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:06 pm

ACTU

Actuate Therapeutics announced promising initial data on the combination of Elraglusib with FOLFIRINOX and Losartan for treating metastatic pancreatic cancer. The data, presented at the AACR conference, showed deep, durable responses in patients, highlighting the potential of this combination therapy.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:05 pm